The reimbursement standard has been set for Qarziba (dinutuximab, Recordati Korea), which was designated as the 1st drug for a “Pilot Project for Integration of Product Approvals, Reimbursement Coverage Reviews, and Drug Price Negotiations,” even though it has not yet received approval from the Ministry of Food and Drug Safety (MFDS).

Qarziba is used for treating neuroblastoma in young children over 12 months.

The Health Insurance Review and Assessment Service (HIRA) held the 4th Cancer Disease Review Committee (CDRC) meeting 2024 on May 29 and announced this review result.

Qarziba was considered for a review as a novel drug. It has been assigned to a “Pilot Project for In